News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|May 12, 2025

Present and Looking to the Future: Lp(a) Testing and Atherosclerotic Disease Management

Author(s)Nihar Desai, MD, MPH, Nathan Wong, PhD, Jeremy Wigginton, MD, MBA, FAAFP

Experts share their final thoughts on the discussion, offering key takeaways and reflections on the importance of lipoprotein(a) (Lp[a]) testing and its role in improving cardiovascular risk management

Episodes in this series

EP. 1 Lp(a) in ASCVD and Guideline Recommendations

EP. 1 Lp(a) in ASCVD and Guideline Recommendations

EP. 2 Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis

EP. 2 Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis

EP. 3 The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis

EP. 3 The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis

EP. 4 Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease

EP. 4 Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease

EP. 5 Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime

EP. 5 Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime

EP. 6 How the Genetic Nature of Lp(a) Levels Influences Screening

EP. 6 How the Genetic Nature of Lp(a) Levels Influences Screening

EP. 7 A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk

EP. 7 A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk

EP. 8 The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations

EP. 8 The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations

EP. 9 Evidence Supporting 2024 Guidance for Lp(a) Testing

EP. 9 Evidence Supporting 2024 Guidance for Lp(a) Testing

EP. 10 Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing

EP. 10 Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing

EP. 11 Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing

EP. 11 Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing

EP. 12 FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels

EP. 12 FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels

EP. 13 The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies

EP. 13 The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies

EP. 14 Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment

EP. 14 Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment

EP. 15 Lp(a) Testing: Prevalence and Strategies to Improve Uptake

EP. 15 Lp(a) Testing: Prevalence and Strategies to Improve Uptake

EP. 16 Implementing Lp(a) Testing in Health Systems: Lessons From Real-World Experience

EP. 16 Implementing Lp(a) Testing in Health Systems: Lessons From Real-World Experience

EP. 17 Implementing Lp(a) Testing: Learning From LDL Testing and Considering Value-Based Care Models

EP. 17 Implementing Lp(a) Testing: Learning From LDL Testing and Considering Value-Based Care Models

EP. 18 Present and Looking to the Future: Lp(a) Testing and Atherosclerotic Disease Management

EP. 18 Present and Looking to the Future: Lp(a) Testing and Atherosclerotic Disease Management

Video content above is prompted by the following:

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Rising columns of coins with an overlaid bar chart | Image credit: THAWEERAT - stock.adobe.com

ICER Draft Flags High Cost of New Hypertension Drug Class

ByLaura Joszt, MA

August 14th 2026

The Endocrinologist's View: Obesity, MASH, and the Metabolic Dysfunction That Connects Them

ByJaime Almandoz, MD, MBA

August 14th 2026

Translating SYNCHRONIZE-1 to Practice: Who May Benefit From Dual GLP-1/Glucagon Receptor Agonism?

ByMazen Noureddin, MD, MHSc

August 14th 2026

2 experts are featured in this video

Hepatitis B Epidemiology: Closing the Screening and Diagnosis Gap

ByRaymond Chung, MD,Douglas Dieterich, MD

August 13th 2026

2 experts are featured in this video

Understanding the Immune Pathophysiology Driving Chronic Hepatitis B

ByRaymond Chung, MD,Douglas Dieterich, MD

August 13th 2026

Trending on AJMC

5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug

Retina Specialists Favor Efficacy Over Risk in Geographic Atrophy Care

ICER Draft Flags High Cost of New Hypertension Drug Class

GLP-1 Use Remains Rare Among Eligible Patients With Multiple Sclerosis

MDS/MPN Response Criteria Tied to Survival